Home › Companies › Corbus Pharmaceuticals Holdings, Inc. › 2025-2026
At Corbus Pharmaceuticals Holdings, Inc.'s shareholder meeting held May 13, 2026, in the 2025-2026 proxy season, 86 asset managers reported how they voted in their SEC Form N-PX filings, covering 481 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE EXECUTIVE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — Corbus Pharmaceuticals Holdings, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Corbus Pharmaceuticals Holdings, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 14, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Corbus Pharmaceuticals Holdings, Inc.’s Form 8-K, filed May 14, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 13, 2026: 9 items on Corbus Pharmaceuticals Holdings, Inc.’s Form 8-K, filed May 14, 2026: 3 approved · 6 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Corbus Pharmaceuticals Holdings, Inc. in the interactive database Compare manager voting policies
These tallies are Corbus Pharmaceuticals Holdings, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 14, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Yuval Cohen | 9,986,956 | -- | -- | 87,114 | 4,060,300 | 99.1% | Not verified | — |
| Elect Director: Rachelle Jacques | 9,647,139 | -- | -- | 426,931 | 4,060,300 | 96% | Not verified | — |
| Elect Director: John Jenkins | 9,636,703 | -- | -- | 437,367 | 4,060,300 | 96% | Not verified | — |
| Elect Director: Anne Altmeyer | 9,621,769 | -- | -- | 452,301 | 4,060,300 | 96% | Not verified | — |
| Elect Director: Yong Ben | 9,988,459 | -- | -- | 85,611 | 4,060,300 | 99.1% | Not verified | — |
| Elect Director: Winston Kung | 9,979,901 | -- | -- | 94,169 | 4,060,300 | 99.0% | Not verified | — |
| 2. Proposal to approve the 2024 Plan Amendment | 5,950,038 | 4,099,773 | 24,259 | -- | 4,060,300 | 59% | Approved | — |
| 3. Proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026 | 14,102,264 | 14,731 | 17,375 | -- | -- | 99.8% | Approved | — |
| 4. Proposal to vote, on an advisory basis, on the compensation of the Company's named executive officers as described in the Company's definitive proxy statement | 9,325,932 | 721,442 | 26,696 | -- | 4,060,300 | 93% | Approved | — |
Source: Corbus Pharmaceuticals Holdings, Inc., Form 8-K, filed with the SEC on May 14, 2026 — read the filing on EDGAR.
Each item below shows how the 86 asset managers that disclosed a Corbus Pharmaceuticals Holdings, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Corbus Pharmaceuticals Holdings, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Anne Altmeyer
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“Elect Director: Anne Altmeyer”): 9,621,769 for, 452,301 withheld, per its Form 8-K filed May 14, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 1,049,318 for, 92 withheld, 1,159 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 746,623 | 0 | 1,159 | 0 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 50,858 | 0 | 0 | 0 | For |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 23,461 | 0 | 0 | 0 | For |
| American Century | 15,139 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,026 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 1,789 | 0 | 0 | 0 | For |
| Northern Trust | 1,777 | 0 | 0 | 0 | For |
| Jackson National | 1,493 | 0 | 0 | 0 | For |
| Nationwide | 1,300 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,173 | 0 | 0 | 0 | For |
| John Hancock | 350 | 0 | 0 | 0 | For |
| State Street | 113 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 92 | Withhold |
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: John Jenkins
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“Elect Director: John Jenkins”): 9,636,703 for, 437,367 withheld, per its Form 8-K filed May 14, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 1,049,318 for, 92 withheld, 1,159 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 746,623 | 0 | 1,159 | 0 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 50,858 | 0 | 0 | 0 | For |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 23,461 | 0 | 0 | 0 | For |
| American Century | 15,139 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,026 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 1,789 | 0 | 0 | 0 | For |
| Northern Trust | 1,777 | 0 | 0 | 0 | For |
| Jackson National | 1,493 | 0 | 0 | 0 | For |
| Nationwide | 1,300 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,173 | 0 | 0 | 0 | For |
| John Hancock | 350 | 0 | 0 | 0 | For |
| State Street | 113 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 92 | Withhold |
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Rachelle Jacques
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“Elect Director: Rachelle Jacques”): 9,647,139 for, 426,931 withheld, per its Form 8-K filed May 14, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 1,049,318 for, 92 withheld, 1,159 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 746,623 | 0 | 1,159 | 0 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 50,858 | 0 | 0 | 0 | For |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 23,461 | 0 | 0 | 0 | For |
| American Century | 15,139 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,026 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 1,789 | 0 | 0 | 0 | For |
| Northern Trust | 1,777 | 0 | 0 | 0 | For |
| Jackson National | 1,493 | 0 | 0 | 0 | For |
| Nationwide | 1,300 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,173 | 0 | 0 | 0 | For |
| John Hancock | 350 | 0 | 0 | 0 | For |
| State Street | 113 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 92 | Withhold |
Combines 5 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Winston Kung
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“Elect Director: Winston Kung”): 9,979,901 for, 94,169 withheld, per its Form 8-K filed May 14, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 1,050,029 for, 541 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 747,242 | 0 | 0 | 541 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 50,858 | 0 | 0 | 0 | For |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 23,461 | 0 | 0 | 0 | For |
| American Century | 15,139 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,026 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 1,789 | 0 | 0 | 0 | For |
| Northern Trust | 1,777 | 0 | 0 | 0 | For |
| Jackson National | 1,493 | 0 | 0 | 0 | For |
| Nationwide | 1,300 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,173 | 0 | 0 | 0 | For |
| John Hancock | 350 | 0 | 0 | 0 | For |
| State Street | 113 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 92 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Yong Ben
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“Elect Director: Yong Ben”): 9,988,459 for, 85,611 withheld, per its Form 8-K filed May 14, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 1,050,569 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 747,782 | 0 | 0 | 0 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 50,858 | 0 | 0 | 0 | For |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 23,461 | 0 | 0 | 0 | For |
| American Century | 15,139 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,026 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 1,789 | 0 | 0 | 0 | For |
| Northern Trust | 1,777 | 0 | 0 | 0 | For |
| Jackson National | 1,493 | 0 | 0 | 0 | For |
| Nationwide | 1,300 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,173 | 0 | 0 | 0 | For |
| John Hancock | 350 | 0 | 0 | 0 | For |
| State Street | 113 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 92 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Yuval Cohen
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“Elect Director: Yuval Cohen”): 9,986,956 for, 87,114 withheld, per its Form 8-K filed May 14, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 1,050,569 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 747,782 | 0 | 0 | 0 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 50,858 | 0 | 0 | 0 | For |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 23,461 | 0 | 0 | 0 | For |
| American Century | 15,139 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,026 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 1,789 | 0 | 0 | 0 | For |
| Northern Trust | 1,777 | 0 | 0 | 0 | For |
| Jackson National | 1,493 | 0 | 0 | 0 | For |
| Nationwide | 1,300 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,173 | 0 | 0 | 0 | For |
| John Hancock | 350 | 0 | 0 | 0 | For |
| State Street | 113 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 92 | 0 | 0 | 0 | For |
59% Approved · of votes cast
Description as filed by funds: APPROVAL OF AN AMENDMENT TO THE CORBUS PHARMACEUTICALS HOLDINGS, INC. 2024 EQUITY COMPENSATION PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY 3,000,000 SHARES TO 5,000,000 SHARES.
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“2. Proposal to approve the 2024 Plan Amendment”): 5,950,038 for, 4,099,773 against — passed, per its Form 8-K filed May 14, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to approve the 2024 Plan Amendment, was approved based on the following votes:”
Support: 59% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 746,616 | 1,166 | 0 | 0 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 0 | 50,858 | 0 | 0 | Against |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 0 | 23,461 | 0 | 0 | Against |
| American Century | 0 | 15,139 | 0 | 0 | Against |
| T. Rowe Price | 0 | 12,026 | 0 | 0 | Against |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 1,789 | 0 | 0 | Against |
| Northern Trust | 0 | 1,777 | 0 | 0 | Against |
| Jackson National | 0 | 1,493 | 0 | 0 | Against |
| Nationwide | 0 | 1,300 | 0 | 0 | Against |
| Lincoln Financial | 0 | 1,173 | 0 | 0 | Against |
| John Hancock | 0 | 350 | 0 | 0 | Against |
| State Street | 0 | 113 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 92 | 0 | 0 | Against |
Fund voting reports, all 17 managers: 939,832 for, 110,737 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Rangeley Capital, LLC | 44,840 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 44,840 for.
Combines 3 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE EXECUTIVE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“4. Proposal to vote, on an advisory basis, on the compensation of the Company's named executive officers as described in the Company's definitive proxy statement”): 9,325,932 for, 721,442 against — passed, per its Form 8-K filed May 14, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to vote, on an advisory basis, on the compensation of the Company's named executive officers as described in the Company's definitive proxy statement was approved based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 747,781 | 1 | 0 | 0 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 0 | 50,858 | 0 | 0 | Against |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 23,461 | 0 | 0 | 0 | For |
| American Century | 0 | 15,139 | 0 | 0 | Against |
| T. Rowe Price | 12,026 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 1,789 | 0 | 0 | 0 | For |
| Northern Trust | 1,777 | 0 | 0 | 0 | For |
| Jackson National | 0 | 1,493 | 0 | 0 | Against |
| Nationwide | 0 | 1,300 | 0 | 0 | Against |
| Lincoln Financial | 0 | 1,173 | 0 | 0 | Against |
| John Hancock | 350 | 0 | 0 | 0 | For |
| State Street | 113 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 92 | 0 | 0 | Against |
Fund voting reports, all 17 managers: 980,513 for, 70,056 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,224,416 | 0 | 0 | 0 | For |
| Aberdeen | 1,321,750 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,292,679 | 0 | 0 | 0 | For |
| Citadel | 521,382 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 383,462 | 0 | 0 | 0 | For |
| Prosight Management, LP | 351,298 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 268,036 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 187,029 | 0 | 0 | 0 | For |
| Global X | 160,218 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 155,000 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 147,623 | 0 | 0 | 0 | For |
| BlackRock | 130,459 | 397 | 0 | 0 | For |
| Vanguard | 103,871 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 85,543 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 79,675 | 0 | 0 | 0 | For |
| Invesco | 0 | 78,238 | 0 | 0 | Against |
| State Street | 68,872 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 64,241 | 0 | 0 | 0 | For |
| Rangeley Capital, LLC | 44,840 | 0 | 0 | 0 | For |
| RBC Capital Markets, LLC | 28,564 | 0 | 0 | 0 | For |
| Renaissance | 26,440 | 0 | 0 | 0 | For |
| Velan Capital Investment Management LP | 26,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 24,052 | 0 | 0 | 0 | For |
| Northern Trust | 22,413 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 19,600 | 0 | 0 | 0 | For |
Institutional-manager reports, all 78 managers: 7,811,268 for, 121,937 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
— Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: TO VOTE, ON AN ADVISORY BASIS, ON HOW OFTEN THE COMPANY WILL CONDUCT AN ADVISORY VOTE ON EXECUTIVE COMPENSATION.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Roundhill ETF Trust | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| Nationwide | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 17 managers: 995,868 1 year, 53,524 3 year, 1,176 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| ORBIMED ADVISORS LLC | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Prosight Management, LP | 0 | 0 | 0 | 0 | -- |
| ARMISTICE CAPITAL, LLC | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| ADAR1 Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| 683 Capital Management, LLC | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| Rangeley Capital, LLC | 0 | 0 | 0 | 0 | -- |
| RBC Capital Markets, LLC | 0 | 0 | 0 | 0 | -- |
| Renaissance | 0 | 0 | 0 | 0 | -- |
| Velan Capital Investment Management LP | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Laurion Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 76 managers: 7,349,483 1 year, 26,000 unknown, 19,180 3 year, 80 2 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: Ratification of the Appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.
Corbus Pharmaceuticals Holdings, Inc.’s own tally for this item (“3. Proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026”): 14,102,264 for, 14,731 against — passed, per its Form 8-K filed May 14, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2026, was approved based upon the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 17 asset managers below reported 1,050,569 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 747,782 | 0 | 0 | 0 | For |
| Fidelity | 151,757 | 0 | 0 | 0 | For |
| Dimensional | 50,858 | 0 | 0 | 0 | For |
| BlackRock | 33,088 | 0 | 0 | 0 | For |
| Roundhill ETF Trust | 23,461 | 0 | 0 | 0 | For |
| American Century | 15,139 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,026 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,496 | 0 | 0 | 0 | For |
| Equitable | 2,875 | 0 | 0 | 0 | For |
| Victory Capital | 1,789 | 0 | 0 | 0 | For |
| Northern Trust | 1,777 | 0 | 0 | 0 | For |
| Jackson National | 1,493 | 0 | 0 | 0 | For |
| Nationwide | 1,300 | 0 | 0 | 0 | For |
| Lincoln Financial | 1,173 | 0 | 0 | 0 | For |
| John Hancock | 350 | 0 | 0 | 0 | For |
| State Street | 113 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 92 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 18,527,795 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.04% |
| 2 | Fidelity | 0.82% |
| 3 | Dimensional | 0.27% |
| 4 | BlackRock | 0.18% |
| 5 | Roundhill ETF Trust | 0.13% |
| 6 | American Century | 0.08% |
| 7 | T. Rowe Price | 0.06% |
| 8 | Goldman Sachs | 0.03% |
| 9 | Equitable | 0.02% |
| 10 | Victory Capital | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Cormorant Asset Management, LP | 12.01% |
| 2 | Aberdeen | 7.13% |
| 3 | ORBIMED ADVISORS LLC | 6.98% |
| 4 | Citadel | 2.81% |
| 5 | Stonepine Capital Management, LLC | 2.07% |
| 6 | Prosight Management, LP | 1.90% |
| 7 | ARMISTICE CAPITAL, LLC | 1.45% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.01% |
| 9 | Global X | 0.86% |
| 10 | Octagon Capital Advisors LP | 0.84% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Cormorant Global Healthcare Master Fund, LP | 12.66% | DEF14A |
| RA Capital Management, L.P. | 10.33% | 13G |
| Cormorant Asset Management, LP | 8.10% | 13G |
| Aberdeen Group plc | 7.13% | DEF14A |
| OrbiMed Capital LLC | 6.33% | DEF14A |
| Octagon Capital Advisors LP | 5.15% | DEF14A |
| Vanguard Group | 4.64% | 13F |
| Citadel Advisors | 4.35% | 13F |
| Renaissance Technologies | 1.87% | 13F |
| Yuval Cohen | 1.76% | DEF14A |
Percentages above are of 18,527,795 shares outstanding, as reported by Corbus Pharmaceuticals Holdings, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Corbus Pharmaceuticals Holdings, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Corbus Pharmaceuticals Holdings, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Corbus Pharmaceuticals Holdings (CRBP) 2026 Annual Meeting”, https://proxyvotesnow.com/company/corbus-pharmaceuticals-holdings-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.